Prof Anton Hagenbeek at ASH 2014: Chimeric antigen receptor (CAR) T-cell immunotherapy for haematological malignancies

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Anton Hagenbeek (Academic Medical Center, Amsterdam, Netherlands) discusses recent investigational advances in chimeric antigen receptor (CAR) T-cell immunotherapy for haematological malignancies, including refractory acute lymphoblastic leukaemia (ALL), chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (diffuse large B-cell lymphoma, follicular lymphoma).